Docosahexaenoic acid (DHA), a type of omega-3 fatty acid, has been reported to reduce dyskinesia in a randomized, multicenter, triple-blind, placebo-controlled phase I study (www.ClinicalTrials.gov, Identifier: NCT01563913)
Muscle loss accelerates
While the rate of GLP-1 prescriptions labeled for type 2 diabetes were about the same as June 2024 (+4.0%), the rate of prescriptions for GLP-1 medications labeled for obesity increased substantially in September 2024 compared to June 2024 (+32.3%)
Patients with genetic variants associated with stronger appetite suppression may benefit from slower dose increases to allow their bodyand menstrual cycletime to adapt
Remember, making small, consistent changes can have a significant impact over time
Only 5 patients stopped the trial from gastrointestinal side effects and only 5% of the 9mg and 12mg arms had to stop the trial for any adverse events